Mobocertinib added in NICE guidelines
NICE guidelines have added the guidance on mobocertinib to the systemic anti-cancer therapy treatment pathways for advanced non-small-cell lung cancer.
They would like your feedback on how the treatment pathways present content from different sources (NICE technology appraisal guidance, guideline recommendations, and expert input). To comment, go to the link below on systemic anti-cancer therapy for advanced non-small-cell lung cancer and fill in the pop-up survey.
Recent Posts
NICE Updates Type 2 Diabetes Guidelines: Emphasizing Cardiorenal Protection with SGLT2 Inhibitors
Type 2 Diabetes Guidelines Reshape Initial Treatment
The latest Type 2 Diabetes Guidelines from NICE (National Institute for Health and Care Excellence), published on 18 February 2026 as an update to guideline NG28 ("Type 2 diabe...
Enhancing Safety and Performance: The Role of EU Medical Device Panels
EU Medical Device Panels: Enhancing Safety and Performance Evaluations
EU Medical Device Panels established by the European Medicines Agency (EMA) provide specialized expertise on clinical and performance evaluat...
Zorginstituut Nederland’s Lecanemab Health Insurance Rejection: Implications for Alzheimer&...
Dutch Health Insurance Rejects Lecanemab Coverage
Zorginstituut Nederland's advisory letter dated 13 February 2026 recommends against including lecanemab (Leqembi®) in the Dutch basic health insurance package, marking a key lecanema...